Graham Capital Management, L.P. Travere Therapeutics, Inc. Transaction History
Graham Capital Management, L.P.
- $5.08 Billion
- Q4 2024
A detailed history of Graham Capital Management, L.P. transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 17,615 shares of TVTX stock, worth $370,443. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,615Holding current value
$370,443% of portfolio
0.01%Shares
5 transactions
Others Institutions Holding TVTX
# of Institutions
213Shares Held
94.1MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$161 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$155 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$142 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$105 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$89.6 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.35B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...